MediLink Dosed 1st Patient in Phase I Study with ADC YL202


MediLink Therapeutics today announced that the first patient has been successfully dosed with its Antibody Drug Conjugate (ADC) product YL202 in the United States and the first dose was well tolerated without any adverse events (AEs) observed. This is a multi-center nonrandomized, open-label, first-in-human phase I study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated Non-small cell lung cancer (NSCLC) or hormone receptor (HR)-positive and HER2-negative breast cancer (BC). “The initiation of this study represents a significant milestone for MediLink Therapeutics, as it marks the second program of our ADC platform to enter the clinic in less than one year”, stated Tony Xue, PhD, Chairman, Founder & CEO.

“We are excited to participate in the development of this novel and targeted ADC approach to cancer treatment”, said Dr. Arvind Chaudhry, M.D., PhD of Summit Cancer Centers, an investigator for the study.

About MediLink Therapeutics

MediLink Therapeutics is a new concept antibody drug conjugate company and has built a differentiated proprietary Tumor Microenviroment Activable LINker (TMALIN) ADC technology platform. It generates homogeneous DAR8 ADC products with potential to resolve drug resistance issues of current ADC products. Headquarter and R&D center located in Suzhou, China and established Clinical Research Centers in both Shanghai and Boston, MediLink Therapeutics focuses its clinical drug development on unmet medical needs and will further expand into new disease areas to serve global patients.

Go list